#nomination

Moderna and Merck's individualized cancer vaccine program appears to have overcome years of skepticism, according to STAT. Anthropic's revenue climbed sharply even as its flagship model reportedly loses ground to cheaper rivals, a tension one developer described as forcing harder choices about AI coding costs. Health policy shifted on several fronts: a Medicaid precedent that could reach far beyond its original target, a new FDA nominee, and a promised FDA guidance on generative AI devices.

OpenAI's GPT-5.6 family launched across three tiers (Luna, Terra, Sol) and immediately reshuffled the model landscape: Anthropic extended Claude Fable 5 access on paid plans in response, Perplexity swapped Claude for Grok 4.5 at half the cost, and one production team reported a 2.2x speed gain and 27% cost reduction after migrating an agent to GPT-5.6. Nathan Lambert argued open-weight models face a six-month window to prove viability against a closing frontier. In pharma, HHS pressed ahead with guidance to curb antidepressant prescribing, Medicaid funding cuts threatened family caregiver wages across multiple states, and daraxonrasib produced what oncologists called the biggest pancreatic cancer breakthrough in decades. Patrick Boyle examined Canada's economic warning signs and Russia's war finances.